FDA Accepts IND for Humacyte's CTEV in First-Ever Human CABG Study
HUMA sits 16% above its 52-week low of $0.547 on light trading volume (0.2× avg).
Summary
The FDA accepted Humacyte's IND for a first-in-human Phase 2a study of its coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting. This is a new pipeline asset, distinct from the already-approved ATEV for vascular trauma. The study will enroll 10 patients, with patency assessed at two months and follow-up to three years. The addressable market is large—over 400,000 coronary grafts annually in the U.S.—and no off-the-shelf conduit has been introduced in 40 years. Preclinical data in baboons showed sustained patency and remodeling, published in JACC: Basic to Translational Science. The company plans to start the trial this quarter. This follows a period of financial strain, including a going concern warning and a recent $50M offering, but the IND acceptance validates the platform's expansion beyond trauma. The stock trades at $0.63, reflecting ongoing dilution risk, but this regulatory milestone could shift sentiment if the trial progresses.
At the time of this announcement, HUMA was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $168.5M. The 52-week trading range was $0.55 to $2.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.